– Seven Abstracts Selected for Poster Presentations –
The details for the data presentations at IDWeek are as follows:
XERAVA Poster Presentations
Poster title: Comparative Evaluation of ETEST® ERV* bioMérieux with the CLSI Broth Microdilution Method for Eravacycline MIC Determination
Authors: Sauvonnet V, Fyfe C, Bouvier M, Fontaine S, Halimi D, Martelin R, Zambardi G
Date and time:
Location: Hall B + C
Poster number: 644
Session information: New Diagnostics
Poster title: In vitro Activity of Eravacycline, a New Tetracycline Analog, and Comparators Against the Six Most Commonly Isolated Ribotypes of Clostridioides difficile
Authors: Basseres E, Miranda J, Gonzales-Luna A, Carlson T, Rashid T, Alam MJ, Garey K
Date and time:
Location: Hall B + C
Poster number: 688
Session information: Novel Antimicrobials and Approaches Against Resistant Bugs
Poster title: In vitro Activity and Performance of Available Susceptibility Testing Methods for Eravacycline Against Carbapenem-Resistant Enterobacteriaceae
Authors: Jones C, Kline E, Nguyen MH, Clancy C, Shields R
Date and time:
Location: Hall B + C
Poster number: 710
Session information: Novel Antimicrobials and Approaches Against Resistant Bugs
Poster title: Activity of Eravacycline Against Contemporary Gram-negative Clinical Isolates from New York City Hospitals
Authors: Iregui A, Khan Z, Landman D, Quale J
Date and time:
Location: Hall B + C
Poster number: 728
Session information: Novel Antimicrobials and Approaches Against Resistant Bugs
Poster title: Multicenter Evaluation of Eravacycline MIC Results for Enterobacteriaceae Using MicroScan Dried Gram-Negative MIC Panels
Authors: Traczewski M, Beasley D, Harrington A, DesJarlais S, Garner O, Hastey C, Brookman R, Lockett Z, Chau J, Zimmer B
Date and time:
Location: Hall B + C
Poster number: 2132
Session information: Bacterial Diagnostics
Poster title: Predictors of Empiric Carbapenem Therapy in Complicated Intra-Abdominal Infections in the US, 2013-2017: A Retrospective Cohort Study
Authors: Zilberberg M, Nathanson B, Lawrence K, Johnson C, Ditch K, Olesky M, Shorr A
Date and time:
Location: Hall B + C
Poster number: 2259
Session information: Clinical Outcomes of Infections with Resistant Organisms
Poster title: An Evaluation of Empiric Treatment Patterns for Adult Patients with Community-Onset “Low-Risk” Complicated Intra-Abdominal Infections Across US Hospitals
Authors: Lodise T, Izmailyan S, Olesky M, Lawrence K, Tsai L
Date and time:
Location: Hall B + C
Poster number: 2264
Session information: Clinical Outcomes of Infections with Resistant Organisms
Additional Activities
-
Tetraphase will host a XERAVA exhibit booth (#1125) at IDWeek 2019 during exhibit hours:
Thursday, October 4 ; from11:45 a.m. –6:00 p.m. ET ;Friday, October 5 from10:00 a.m. –4:00 p.m. ET ; andSaturday, October 6 from10:00 a.m. –2:00 p.m. ET . Tetraphase Medical Affairs also will be present at booth #1125 during exhibit hours.
IDWeek is the combined annual meeting of the
About XERAVA™
XERAVA (eravacycline for injection) is a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. XERAVA was investigated for the treatment of cIAI as part of the Company's IGNITE (Investigating Gram-Negative Infections Treated with Eravacycline) phase 3 programs. In the first pivotal phase 3 trial in patients with cIAI, twice-daily intravenous (IV) XERAVA met the primary endpoint by demonstrating statistical non-inferiority of clinical response compared to ertapenem and was well-tolerated. In the second phase 3 clinical trial in patients with cIAI, twice-daily IV XERAVA met the primary endpoint by demonstrating statistical non-inferiority of clinical response compared to meropenem and was well-tolerated. In both trials, XERAVA achieved high cure rates in patients with Gram-negative pathogens, including resistant isolates.
Important Safety Information
To report SUSPECTED ADVERSE REACTIONS, contact
Please see full prescribing information for XERAVA at www.XERAVA.com.
About
View source version on businesswire.com: https://www.businesswire.com/news/home/20190925005261/en/
Source:
Media and Investor Contact:
Argot Partners
Maeve Conneighton
212-600-1902
maeve@argotpartners.com